The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.50
Bid: 18.00
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.556%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

9 Nov 2018 10:30

RNS Number : 9140G
Renalytix AI PLC
09 November 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

Renalytix AI Plc

(LEI: 213800NTOH3FK3WER551)

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

 

Legal & General Group Plc (Group)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name

 

Legal & General Assurance Society (LGAS)

 

Legal & General Assurance

(Pensions Management) Limited (PMC)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

6TH November 2018

6. Date on which issuer notified (DD/MM/YYYY):

 

8TH November 2018

 

 

 

 

 

 

 

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

 

3.10%

 

-

 

3.10%

 

 

53,816,134

 

Position of previous notification (if

applicable)

 

First disclosure under DTR Sourcebook

 

-

 

First disclosure under DTR Sourcebook

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD 0.25P

GB00BYWL4Y04

1,672,096

 

-

 

3.10%

 

-

SUBTOTAL 8. A

1,672,096

3.10%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

 

Below 5%

 

Below 5%

 

Legal & General Group (Direct)

 

3.10%

 

 

3.10%

 

 

Legal & General Assurance Society (Direct)

Below 3%

Below 3%

 

 

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

 

Below 5%

 

Below 5%

Legal & General Group (Direct)

 

3.10%

 

 

3.10%

 

Legal & General Assurance (Pensions Management) Limited

(Direct)

Below 3%

Below 3%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

 

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

 

 

 

Below 5%

 

 

 

Below 5%

Legal & General Investment Management Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

Below 5%

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Legal & General (Unit Trust Managers) Limited (Indirect)

Below 5%

Below 5%

Legal & General Group (Direct/Indirect)

 

Below 5%

 

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Below 5%

Go ETF

0%

0%

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 53,816,134

 

 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

08/11/2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLMMMGMGLRGRZM
Date   Source Headline
6th Aug 20214:42 pmRNSDirector/PDMR Dealing
2nd Aug 202112:00 pmRNSTotal Voting Rights
30th Jul 20214:25 pmRNSDirector/PDMR Dealing
28th Jul 20217:00 amRNSAppointment of Ann Berman to Board of Directors
23rd Jul 202111:30 amRNSDirector/PDMR Shareholding
22nd Jul 20217:00 amRNSVP of Global Quality and Regulatory Appointment
19th Jul 20213:02 pmRNSExercise of Options and TVR
7th Jul 20217:00 amRNSExercise of options, PDMR transaction and TVR
1st Jul 20213:51 pmRNSDirectorate Change
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 202111:50 amRNSDirector/PDMR Shareholding
28th Jun 20217:00 amRNSNew data for KidneyIntelX
25th Jun 20215:25 pmRNSDirector/PDMR Dealing
25th Jun 202112:52 pmRNSExercise of options
24th Jun 20212:00 pmRNSChange of name
22nd Jun 20211:25 pmRNSDirector/PDMR Shareholding - Replacement
22nd Jun 202110:57 amRNSDirector/PDMR Shareholding
15th Jun 20217:00 amRNSFinancial Results for Third Quarter of FY 2021
10th Jun 20217:00 amRNSNotice of Results & Change of Auditor
7th Jun 20217:00 amRNSKey new hires to drive commercialization strategy
3rd Jun 20217:00 amRNSUtility Study
25th May 20217:00 amRNSDirector/PDMR Shareholding
21st May 20217:02 amRNSDirector/PDMR Dealing
19th May 20218:00 amRNSPartnership
22nd Apr 20212:06 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 202111:05 amRNSSecond Price Monitoring Extn
22nd Apr 202111:00 amRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNS10-year US Government contract award
20th Apr 20217:00 amRNSPositive clinical outcome data for KidneyIntelX
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
14th Apr 20217:00 amRNSExclusive option agreement
8th Apr 20217:00 amRNSClinical Utility Study
6th Apr 20217:00 amRNSClinical findings published in Diabetologia
15th Mar 20217:00 amRNSUpdate on Finalization of MCIT Rule
4th Mar 20216:00 pmRNSIssue of shares, PDMR Dealing and TVR
2nd Mar 20217:02 amRNSFinancial Results for Second Quarter of FY 2021
2nd Mar 20217:00 amRNSHalf-year Report
24th Feb 20217:00 amRNSUniversity of Utah Kidney Health Partnership
23rd Feb 20217:00 amRNSNotice of Results
4th Feb 20217:00 amRNSASN & Renalytix to Co-Host Capital Markets Day
13th Jan 20214:35 pmRNSPrice Monitoring Extension
13th Jan 20217:00 amRNSFinalization of MCIT rule for coverage pathway
5th Jan 20214:41 pmRNSSecond Price Monitoring Extn
5th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSPartnership Between RenalytixAI and DaVita
4th Jan 20217:00 amRNSRENX to present at 39th JP Morgan Healthcare Conf.
7th Dec 20203:45 pmRNSResult of AGM
2nd Dec 20201:08 pmRNSPartnership with National Kidney Foundation
26th Nov 20207:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.